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We have shown that both free fatty acids (FFA)
and triglycerides (TG) increase expression of
plasminogen activator inhibitor type 1 (PAI-1)
in vivo and in vitro. To determine signaling
mechanisms responsible, HepG2 cells were
exposed to FFA, emulsified TG, or the combi-
nation. The combination of FFA and TG
increased PAI-1 to a greater extent than either
agent alone (fold induction: 0.45mM FFA
1.7±0.2, 1000mg/dl TG 1.9±0.1, both 2.3±0.2,
n=10, p<0.05 for comparison of combination
with either alone). Cells transfected with PAI-1
5’ flanking region containing the 4G or 5G
polymorphism displayed similar activity in
response to FFA, but modestly greater activity
with the 4G polymorphism in response to TG
(fold induction: 5G-1.28±0.14 and 4G-
1.46±0.13, n=6, p<0.05 for comparison).
Deletion analyses demonstrated that FFA and
TG induce PAI-1 expression through distinct
regions of the promoter. Inhibition of protein
kinase C inhibited the response to FFA but not
TG. Accordingly, increased FFA and TG con-
tribute to increased PAI- I through independent
mechanisms.
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Cardiovascular disease is the leading cause
of death in patients with diabetes, particularly
type 2 diabetes. Patients with type 2 diabetes
have increased concentrations of PAI-1 in
blood and in vessel walls [1, 2, 3, 4]. PAI-1 is
the primary physiologic inhibitor of plasmino-
gen activators, and increased expression of PAI-
1 is likely to accelerate atherogenesis and con-
tribute to an increased incidence of acute
myocardial infarction. Thus, identification of
mechanisms responsible for increased expres-
sion of PAI-1 should facilitate development of
approaches to treatment designed to decrease
expression of PAI-1, retard progression of ath-
erosclerosis, and prevent myocardial infarction.
Both hormonal and metabolic abnormalities
contribute to increased expression of PAI-1 in
diabetes. The concentrations in blood of
triglycerides (TG) and free fatty acids (FFA)
correlate positively with those of PAI-1 [1, 2, 5,
6, 7, 8, 9, 10]. We have reported direct effects
of TG and FFA on expression of PAI-1 in vivo
and in vitro [11, 12]. PAI-1 increases in blood
from healthy human subject during infusion of
glucose and emulsified TG (in combination
with heparin to increase FFA concentrations).
We and others have shown that both TG and
FFA increase expression of PAI-1 in human
hepatoma (HepG2) cells [5, 12, 13, 14, 15, 16,
17, 18, 19]. 
VLDL has been shown to augment expres-
sion of PAI-1 in endothelial cells by increasing
the binding of a VLDL-inducible transcription
factor to the PAI-1 promoter [13,  14]. We have
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FIGURE 1
FFA and TG augmented accumulation of PAI-1 in media conditioned by HepG2 cells. HepG2 cells (80% confluent) were
exposed to serum-free DME/F12 for 8 hours and subsequently to fatty acid free BSA, 3% BSA (0.45mM FFA),
1000mg/dl Liposyn® or the combination of FFA and TG for 24 hours. The concentrations of PAI-1 were determined by
ELISA in conditioned media. Values are means ± SD and represent results in 10 determinations in each case (p< 0.001
compared with control, p<0.05 for the combination compared with either treatment alone).recently identified a FFA response region in
human PAI-1 5’ flanking DNA that is distinct
from the VLDL response region [16]. Because
VLDL contains both TG and FFA, the present
studies were designed to determine whether
FFA and TG augment expression of PAI-1
through independent signaling pathways.
MATERIALS AND METHODS
CELL CULTURE
HepG2 cells were obtained from American
Type Culture Collection and grown in minimal
essential media (MEM, Gibco-BRL) with 10%
Nuserum (Gibco-BRL). Experiments were per-
formed in Dulbeccos’ modified Eagles media
with Hams’ nutrient mixture F12 (DME-F12,
Gibco-BRL).
FFA AND TG PREPARATION AND TREATMENT
3% bovine serum albumin (BSA) and select-
ed concentrations of TG (50mg/dl, 100mg/dl,
500mg/dl and 1000mg/dl Liposyn®) were pre-
pared in DME/F12. 3% BSA containing media
were adjusted to pH 7.4 and filtered through a
0.22 mm filter. We found that 3% BSA in
DME/F12 contains 0.45 mM FFA (Wako
NEFA C kits, Biochemical Diagnostics). 80%
confluent HepG2 cells were pre-incubated in
serum-free DME/F12 for 4 to 8 hours.
Subsequently, experiments were performed in
DME/F12 with FAF-BSA, DME/F12 with BSA,
or DME/F12 with Liposyn®. 
PROTEIN KINASE C (PKC) INHIBITOR
H-7 (Calbiochem), a broad based serine-
threonine kinase inhibitor and Bisindoly-
lmaleimide I (Calbiochem), a highly selective
cell-permeable PKC inhibitor (Ki=10nM) were
added to cells exposed also to FFA or TG. Both
H-7 and Bisindolymaleimide I were dissolved in
DME/F12.
DETECTION OF PAI-1 ANTIGEN
Conditioned media were collected 24 hours
after treatment and assayed for PAI-1 by
ELISA. (Tintelize, Biopool). 
CONSTRUCTION OF PAI-1 PROMOTER-
LUCIFERASE REPORTER PLASMIDS
PAI-LUC 1313 and PAI-LUC 328, contain-
ing 1313 bp or 328 bp of 5’-flanking (-1313)
and 74 bp of the untranslated first exon (+74)
of human PAI-1 DNA upstream of the
luciferase reporter in plasmid pGL3-Basic
(Promega), were generated as described [16]. A
72 bp fatty acid response region (-599 to -528)
was deleted from PAI-LUC 1313 to make PAI-
LUC 1313-72. PAI-LUC 1313-120 was gener-
ated by deletion of a 120 bp Pml I fragment (-
680 to -560) from PAI-LUC 1313. 
PAI LUC 4G was generated by replacing the
5G region in PAI LUC 1313 with 4G contain-
ing fragment by PCR with primers synthesized
by Sigma Genosys: 5’-tgg tca cgt ggg gag tca
gcc gt-3’ and 5’-tgg tgg agg tcc ttt ctc-3’. The
sequence was confirmed by sequence analysis. 
TRANSIENT TRANSFECTION
HepG2 cells were transfected with the use of
the calcium-phosphate precipitation method
[16]. pRL-CMV, a plasmid with Renilla
luciferase gene downstream of the CMV pro-
moter, was used to assess transfection efficien-
cy. Luciferase activity was detected in cell
extracts with the Passive Lysis Buffer in the
Dual-Luciferase Reporter Assay System
(Promega). Luciferase activities were deter-
mined by Dual-Luciferase Reporter Assays
with a DLReady luminometer (Turner Designs
Instrument). 
STATISTICAL ANALYSIS
Results are means ± SD. Differences between
two groups were identified with Student’s t
tests. For multiple groups one-way analysis of
variance and Student-Newman-Keuls Tests
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FIGURE 2
TG increased 24-hour accumulation of PAI-1 in a dose-dependent manner. HepG2 cells (80% confluent) were exposed
to serum-free DME/F12 for 8 hours and subsequently to selected concentrations of Liposyn® for 24 hours. The con-
centration of PAI-1 was determined by ELISA in conditioned media. Values are means ± SD of 6 determinations in each
case (p< 0.05 for 50mg/dl and 100mg/dl and p<0.001 for 200mg/dl and greater compared with control). 
FIGURE 3
Luciferase activity in proteins extracted from HepG2 cells transfected with 1313 bp of the 5’ flanking DNA containing
the 4G or 5G polymorphism at -675. Transient transfection of HepG2 cells was performed with the use of calcium-phos-
phate precipitation. HepG2 cells were co-transfected with PAI-LUC constructs and pRL-CMV, a plasmid containing a
Renilla luciferase gene downstream of the CMV promoter, to control for transfection efficiency. Cells were incubated in
serum-free media for 8 hours and then exposed to fatty acid free (FAF) BSA, 3% BSA (0.45mM FFA), or 1000mg/dl
Liposyn® in DMEM/F12 for 24 hours. HepG2 cell extracts were prepared with Passive Lysis Buffer in the Dual-
Luciferase Reporter Assay System and luciferase activities were determined with the Dual-Luciferase Reporter Assay on
a DLReady luminometer. Results are the means   SD of 6 determinations (p<0.001 for the PAI-LUC 1313 constructs
compared with control, p<0.05 for the PAI-LUC 1313-4G compared with PAI-LUC 1313-5G after exposed to TG). were used to identify differences. Significance
was defined as p < 0.05.
RESULTS
FFA AND TG INCREASE EXPRESSION OF PAI-1 
Both FFA (3% BSA) and TG (1000mg/dl
Liposyn®) increased 24-hour accumulation of
PAI-1 (Figure 1). Similar to previously reported
results with FFA [16], a concentration depend-
ent increase in 24-hour accumulation of PAI-1
was seen after exposure of cells to TG (Figure
2). The combination of FFA and TG yielded
greater effects than either agent alone (Figure 1,
n=10, p<0.05 for combination compared with
each agent alone). 
FFA AND TG INCREASE LUCIFERASE ACTIVITY
Both FFA and TG increased luciferase activ-
ity (corrected for transfection efficiency) in
extracts from HepG2 cells transfected with a
chimeric gene with 1313 bp of human PAI-1 5’
flanking DNA upstream of a luciferase reporter
(PAI-LUC 1313) but not with PAI-LUC 328
(328 bp of human PAI-1 5’ flanking DNA
upstream of a luciferase reporter, Figure 3).
DIFFERENTIAL EFFECTS OF THE 4G AND 5G
POLYMORPHISM
Luciferase activity was increased similarly
when cells were transfected with PAI-LUC
1313 containing the 4G or 5G polymorphism
(at -675 in the PAI-1 gene) and exposed subse-
quently to FFA (Figure 3). Cells transfected
with PAI-LUC 1313 containing the 4G poly-
morphism exhibited modestly greater luciferase
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FIGURE 4
Deletion analysis of the PAI-1 promoter. HepG2 cells were transiently transfected with PAI-1 promoter constructs PAI
LUC 1313-72 (deletion of -528 to –599 from PAI LUC 1313) or PAI LUC 1313-120 (deletion of -680 to –560 from PAI
LUC 1313). The Renilla Luciferase reporter pRL-CMV was co-transfected to control for transfection efficiency. Cells
were incubated in serum-free media for 8 hours and then exposed to fatty acid free BSA (FAF-BSA), 3% BSA (0.45mM
FFA) or 1000 mg/dl Liposyn® for 24 hours. Luciferase activity was determined by Dual-Luciferase Reporter Assay.
Results are mean   SD of 6 determinations (p<0.05 for PAI-LUC 1313-72 when TG was FFA or control, and for PAI-
LUC 1313-100 when FFA was compared with TG or control).activity in response to TG (fold induction with
1000 mg/dl Liposyn® 1.28 ± 0.14 (with the 5G
polymorphism) and 1.46 ± 0.13 (with the 4G
polymorphism), figure 3, n=6, p<0.05 for the
comparison of 5G to 4G). 
PAI-1 PROMOTER DELETION ANALYSIS
Deletion of a 72 bp segment (-528 to -599)
from PAI-LUC 1313 abolished the response to
FFA but did not affect the response to TG
(Figure 4). Deletion of a 120 bp segment (-680
to -560) from PAI-LUC 1313 abolished the
response to TG but did not affect response to
FFA (Figure 4). 
FFA, TG AND PROTEIN KINASE C ACTIVITY IN
HEPG2 CELLS
Both H-7 (H), a broad based serine-threo-
nine kinase inhibitor, and Bisindolylmaleimide I
(B), a highly selective cell-permeable protein
kinase C inhibitor (Ki=10 nM), inhibited the
FFA-induced increased expression of PAI-1 in
HepG2 cells by more than 90%. By contrast,
these agents inhibited the increased expression
of PAI-1 induced by TG by only 30% (Figure
5). Greater concentrations of H-7 attenuated
the TG-induced increased expression of PAI-1
to a greater extent (Figure 5). 
DISCUSSION
Elevated concentrations of PAI-1 in blood
are associated with obesity, insulin resistance,
diabetes and cardiovascular disease [1, 2, 3, 9,
10]. The concentrations of TG and FFA corre-
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FIGURE 5
The Effect of an inhibitor of Protein Kinase C (Bisindolylmaleimide I, [B]) and that of a broad serine-threonine kinase
inhibitor (H-7, [H]) on the increased expression of PAI-1 induced by TG and FFA. 80% confluent HepG2 cells were
exposed to serum free DME/F12 for 8 hours and then treated simultaneously with indicated concentrations of the
inhibitors plus either 3% BSA (0.45mM FFA), or 1000mg/dl Liposyn®. Conditioned media were collected 24 hours later,
and the concentration of PAI-1 was determined by ELISA. Values are means ± SD of 8 determinations in each case
(p<0.001 for no inhibitors compared with inhibitors in response to FFA and TG).late positively with that of PAI-1 [1, 2, 5, 6, 9].
Agents that lower concentrations of TG lead to
a decrease in the concentration of PAI-1 [5, 8,
17, 18, 19]. Our results demonstrated that both
TG and FFA increase PAI-1 through diverse
pathways. 
Our previous results demonstrated that FFA
augment expression of PAI-1 in HepG2 cells
through induction of a transcription factor that
binds to FFA response element located between
–528 and –599 in the PAI-1 gene [16]. The
present results extend the observations and
demonstrate that protein kinase C is a critical
component of the FFA signaling pathway.
Furthermore, our results demonstrate that TG
per se, rather than its constituent FFA alone,
increases expression of PAI-1.
Our results with TG are consistent with
those of Eriksson and colleagues demonstrating
that VLDL augments expression of PAI-1
through a response element located between
–672 and –657 in the PAI-1 gene [13]. Further,
our results in combination with those of
Eriksson et al suggest that TG is the moiety in
VLDL predominately responsible for the effect
of VLDL on the expression of PAI-1 [12,  14,
20] . In addition, the results are consistent with
the observation that the TG content of LDL
modulates expression of PAI-1 [20].
Nevertheless, the additive effect of FFA and TG
demonstrated in the present studies suggest that
the prevailing concentration of both TG and
FFA contribute to the expression of PAI-1 in
diabetic subjects.
Our results are consistent with those in our
previous work in healthy human subjects in
which infusion of Liposyn® and glucose
increased expression of PAI-1 [11]. They
explain, in part, the apparent discrepancy
between results in vivo [21, 22] and in vitro
[23, 24, 25] regarding the effect of insulin on
expression of PAI-1. Thus, a reduction in vivo
in the concentration of TG and FFA associated
with infusion of insulin under euglycemic
clamp techniques [11] would be expected to
negatively affect PAI-1 expression. Accordingly,
potentially positive effects of insulin would be
offset by negative effects association with a
reduction in the concentration of TG and FFA.
Our results are consistent with the view that
the combination of increased glucose, increased
TG, increased FFA, and increased insulin and
insulin precursors augment expression increase
PAI-1 in patients with type 2 diabetes. 
The insertion/deletion polymorphism of PAI-
1 at –675 in the PAI-1 gene has been variably
linked with altered expression of PAI-1 in
healthy subjects and in patients with diabetes
[15, 26, 27, 28]. As expected based on the locus
of the FFA response element, similar effects
were seen with either the 4G or 5G polymor-
phism in response to FFA. By contrast, the
4G/5G polymorphism is located in the TG
response element. Consistent with this location
we found that the 4G polymorphism conferred
a modest increase in sensitivity to TG. These
results are concordant with previous observa-
tions of TG effects on PAI-1 as well as the mod-
est influence of the 4G/5G polymorphism [13,
15,  29]. 
Activation of protein kinase C mediates the
effects of diverse agonists on the expression of
PAI-1 [30, 31, 32, 33]. Protein kinase C con-
tributes to the induction of PAI-1 by phorbol
esters, TNF-alpha, and TGF-beta in diverse cell
types [32, 34, 35, 36], including HepG2 cells
[32, 37], mesangial cells [30, 38], and endothe-
lial cells [31, 33, 34]. In the present studies we
used both H-7, a broad based serine-threonine
kinase inhibitor and Bisindolylmaleimide I, a
highly selective cell-permeable protein kinase C
inhibitor. The FFA-induced increased expres-
sion of PAI-1 was attenuated more than 90%
by either agent. By contrast, the TG-induced
increased expression of PAI-1 was inhibited
only 30% by the protein kinase C specific
inhibitor Bisindolylmaleimide I. Higher con-
centrations of the broad based kinase inhibitor,
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kinases, inhibited the effect of TG. Thus, the
results demonstrate that serine-threonine kinas-
es mediate effects of both TG and FFA on
expression of PAI-1. Hydrolysis of TG yields
FFA. The limited inhibitory effect of the selec-
tive protein kinase C inhibitor on the increased
expression of PAI-1 is consistent with FFA
mediating a component of the TG-induced
effect [18, 39, 40].
In summary, our results demonstrate that TG
and FFA increase expression of PAI-1 through
independent signaling pathways. The effects of
FFA are mediated by protein kinase C and a
FFA response region that is located between
–528 and –599 in the PAI-1 gene. By contrast,
the effects of TG are mediated by a distinct
region (-672 to -657), influenced to a modest
extent by the 4G/5G polymorphism, and
induced by a serine-threonine kinase other than
protein kinase C. 
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